From: Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD
Characteristic | Hospitalizations of patients under biologic therapy n = 56 | Hospitalizations of patients naïve to biologic therapy n = 162 | p |
---|---|---|---|
Age (year) | 15.4 (12.2–17.2) | 14.8 (11.3–16.4) | 0.124 |
Males, n | 29 (47.9%) | 73 (45.1%) | 0.385 |
Crohn’s disease | 31 (55.4%) | 116 (71.6%) | 0.025 |
Ulcerative colitis | 25 (44.6%) | 46 (28.4%) | |
Duration from IBD diagnosis (year) | 3.15 (1.14–4.13) | 2 (0.5–4.15) | 0.070 |
Indication of hospitalization: | 0.945 | ||
IBD exacerbation | 50 (89.3%) | 144 (88.9%) | |
Therapy-related adverse events | 6 (10.7%) | 18 (11.1%) | |
Therapy at admission | |||
5-ASA | 24 (42.9%) | 94 (58%) | 0.049 |
Corticosteroids | 9 (16.1%) | 37 (22.8%) | 0.285 |
Enteral nutrition | 14 (25%) | 30 (18.5%) | 0.297 |
Methotrexate | 2 (3.6%) | 3 (1.9%) | 0.459 |
Azathioprine | 14 (25%) | 68 (42%) | 0.024 |
Disease activity at admission | 0.755 | ||
Remission | 3 (5.3%) | 4 (2.5%) | |
Mild | 23 (41.1%) | 69 (42.6%) | |
Moderate | 23 (41.1%) | 66 (40.7%) | |
Severe | 7 (12.5%) | 23 (14.2%) | |
Length of hospitalization | 5 (2.75–7) | 4 (2–7) | 0.136 |
Blood cultures | 32 (57.1%) | 70 (43.2%) | 0.072 |
Stool culture | 19 (33.9%) | 41 (25.3%) | 0.213 |
Imaging studies | 35 (62.5%) | 113 (69.8%) | 0.316 |
US | 16 (28.6%) | 66 (40.1%) | 0.105 |
CT | 5 (8.9%) | 18 (11.1%) | 0.647 |
MRI | 1 (1.8%) | 2 (1.2%) | 0.760 |
Endoscopy | |||
Upper GI endoscopy | 3 (5.3%) | 16 (9.9%) | 0.301 |
Lower GI endoscopy | 6 (10.7%) | 21 (13%) | 0.660 |
Antibiotics | 30 (53.6%) | 79 (48.8%) | 0.385 |
Blood transfusion | 6 (10.7%) | 8 (4.9%) | 0.129 |
Surgery | 3 (5.4%) | 11 (6.8%) | 0.706 |
Abscess drainage | 2 (3.6%) | 8 (4.9%) | |
Ileo-cecectomy | 0 | 1 (0.6%) | |
Others | 1 (1.8%) | 2 (1.2%) |